Evidence map›Paper›PMID 38895338›Full record

ArticlebioRxiv : the preprint server for biology2024

A mouse model of TB-associated lung fibrosis reveals persistent inflammatory macrophage populations during treatment.

Julie Boucau, Threnesan Naidoo, Yuming Liu, Shatavisha Dasgupta, Neha Jain, Jennie Ruelas Castillo, Nicholas E Jacobson, Kievershen Nargan, Beth A Cimini, Kevin W Eliceiri and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julie BoucauThe Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA.
Threnesan NaidooAfrica Health Research Institute (AHRI), University of Kwazulu-Natal, Durban, South Africa.
Yuming LiuCenter for Quantitative Cell Imaging, University of Wisconsin-Madison, Madison, WI, USA.
Shatavisha DasguptaThe Broad Institute, Cambridge, MA, USA.
Neha JainThe Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA.
Jennie Ruelas CastilloThe Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA.
Nicholas E JacobsonCenter for Quantitative Cell Imaging, University of Wisconsin-Madison, Madison, WI, USA.
Kievershen NarganAfrica Health Research Institute (AHRI), University of Kwazulu-Natal, Durban, South Africa.
Beth A CiminiThe Broad Institute, Cambridge, MA, USA.ORCID 0000-0001-9640-9318
Kevin W EliceiriCenter for Quantitative Cell Imaging, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-8678-670X
Adrie J C SteynAfrica Health Research Institute (AHRI), University of Kwazulu-Natal, Durban, South Africa.
Amy K BarczakThe Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Center for Open Bioimage AnalysisP41GM135019 · NIGMS · BROAD INSTITUTE, INC. · PI CARPENTER, ANNE E., CIMINI, BETH · 2020 to 2024
$6.9M
Elucidating the path to type I IFNs in TB infectionR01AI150762 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BARCZAK, AMY K · 2021 to 2025
$3.2M
Quantitative histopathology for cancer prognosis using quantitative phase imaging on stained tissuesR01CA238191 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ANASTASIO, MARK A, ELICEIRI, KEVIN WILLIAM · 2019 to 2023
$3.1M
METABOLIC REPROGRAMMING OF T CELL ENERGY METABOLISM IN TUBERCULOSIS AND HIVR33AI138280 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STEYN, ADRIE JC · 2020 to 2023
$2.0M
Targeting MT1-MMP to inhibit pathologic inflammation in TBR21AI146813 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BARCZAK, AMY K · 2019 to 2020
$418k
NCI NIH HHS R01 CA238191NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI150762NIAID NIH HHS R21 AI146813NIAID NIH HHS R33 AI138280NIGMS NIH HHS P41 GM135019Wellcome Trust
6 · The paper itself

Abstract

Post-TB lung disease (PTLD) causes a significant burden of global disease. Fibrosis is a central component of many clinical features of PTLD. To date, we have a limited understanding of the mechanisms of TB-associated fibrosis and how these mechanisms are similar to or dissimilar from other fibrotic lung pathologies. We have adapted a mouse model of TB infection to facilitate the mechanistic study of TB-associated lung fibrosis. We find that the morphologies of fibrosis that develop in the mouse model are similar to the morphologies of fibrosis observed in human tissue samples. Using Second Harmonic Generation (SHG) microscopy, we are able to quantify a major component of fibrosis, fibrillar collagen, over time and with treatment. Inflammatory macrophage subpopulations persist during treatment; matrix remodeling enzymes and inflammatory gene signatures remain elevated. Our mouse model suggests that there is a therapeutic window during which adjunctive therapies could change matrix remodeling or inflammatory drivers of tissue pathology to improve functional outcomes after treatment for TB infection.

Identifiers

PMID38895338
PMCPMC11185692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.